LH vs OPK
LH: A global diagnostics and drug development laboratory leader that performs 750+ million clinical tests annually and supports 85% of new FDA-approved drugs through comprehensive testing capabilities. OPK: OPKO Health is a diversified healthcare company balancing a proprietary pharmaceutical and vaccine pipeline with a commercial clinical laboratory testing business.
Side-by-side fundamentals
| Metric | LH | OPK | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $301.17 | $1.24 | |
| Market cap as of 2026-07-28 | $24.7B | $925M | |
| P/E as of 2026-07-28 | 26.69 | n/a | |
| PEG as of 2026-07-28 | 2.76 | -0.02 | OPK lower |
| Net margin as of 2026-07-28 | +6.7% | -36.5% | LH higher |
| Gross margin as of 2026-07-28 | +28.8% | +38.0% | OPK higher |
| Operating margin as of 2026-07-28 | +10.2% | -33.2% | LH higher |
| ROE as of 2026-07-28 | +10.9% | -16.7% | LH higher |
| ROA as of 2026-07-28 | +5.1% | -10.9% | LH higher |
| Debt / equity as of 2026-07-28 | 0.73 | 0.29 | OPK lower |
| Revenue growth (YoY) as of 2026-07-28 | +7.3% | -29.0% | LH higher |
| Revenue CAGR (3y) SEC XBRL | +5.6% | -15.5% | LH higher |
| Dividend yield as of 2026-07-28 | +1.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-07-28 | 0.87 | 1.50 | |
| 1-year return as of 2026-07-27 close | +13.7% | -9.5% | LH higher |
Fundamentals: Finnhub, as of 2026-07-28. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.